IQVIA Holdings Inc. (NYSE:IQV – Get Rating) has received an average recommendation of “Moderate Buy” from the sixteen brokerages that are covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $257.57.
Several analysts have weighed in on the company. Argus boosted their price target on IQVIA from $260.00 to $275.00 in a research note on Thursday, August 18th. Deutsche Bank Aktiengesellschaft reduced their price target on IQVIA from $290.00 to $270.00 in a report on Tuesday, October 18th. Guggenheim increased their target price on IQVIA to $249.00 in a report on Thursday, October 27th. Barclays increased their target price on IQVIA from $215.00 to $235.00 and gave the company an “overweight” rating in a report on Thursday, October 27th. Finally, Evercore ISI increased their target price on IQVIA from $265.00 to $275.00 in a report on Friday, July 22nd.
Institutional Trading of IQVIA
Several hedge funds have recently modified their holdings of the stock. Pitcairn Co. raised its stake in IQVIA by 101.8% in the first quarter. Pitcairn Co. now owns 2,226 shares of the medical research company’s stock valued at $515,000 after buying an additional 1,123 shares in the last quarter. Raymond James & Associates increased its position in shares of IQVIA by 4.1% during the first quarter. Raymond James & Associates now owns 729,957 shares of the medical research company’s stock worth $168,773,000 after purchasing an additional 28,899 shares in the last quarter. Oppenheimer Asset Management Inc. increased its position in shares of IQVIA by 205.2% during the second quarter. Oppenheimer Asset Management Inc. now owns 14,162 shares of the medical research company’s stock worth $3,074,000 after purchasing an additional 9,522 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of IQVIA during the first quarter worth about $599,000. Finally, Verition Fund Management LLC acquired a new stake in shares of IQVIA during the first quarter worth about $258,000. 86.77% of the stock is currently owned by institutional investors and hedge funds.
IQVIA Stock Down 5.6 %
Shares of IQV stock opened at $211.42 on Friday. IQVIA has a 1-year low of $165.75 and a 1-year high of $285.61. The stock’s fifty day moving average price is $197.14 and its 200 day moving average price is $210.62. The company has a debt-to-equity ratio of 2.29, a current ratio of 0.90 and a quick ratio of 0.90. The company has a market cap of $39.27 billion, a price-to-earnings ratio of 34.43, a price-to-earnings-growth ratio of 2.14 and a beta of 1.37.
IQVIA Company Profile
IQVIA Holdings, Inc engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions and real-world solutions and services to the firm’s life science clients.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider IQVIA, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and IQVIA wasn’t on the list.
While IQVIA currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here